Interferences in laboratory tests: diagnostic criteria for diabetes mellitus and major hypoglycemic agents

Authors

  • Daniela Hisaye KANASHIRO Centro Universitário São Camilo, São Paulo, SP, Brasil
  • Flávia Domingues GAMEIRO Centro Universitário São Camilo, São Paulo, SP, Brasil
  • Válter Luiz da COSTA JÚNIOR Centro Universitário São Camilo, São Paulo, SP, Brasil
  • Alexsandro Macedo SILVA Centro Universitário São Camilo, São Paulo, SP, Brasil
  • Luciane Maria RIBEIRO NETO Centro Universitário São Camilo, São Paulo, SP, Brasil Departamento de Medicina da UNIFESP, São Paulo, SP, Brasil.
  • Reiko Soraya MATSUI Gerência técnica do Centro de Diagnóstico Mello, São Paulo, SP, Brasil.
  • Sandro Jorge JANUÁRIO Centro de Virologia-Núcleo de Doenças Sanguíneas e Sexuais, Instituto Adolfo Lutz de São Paulo, São Paulo, SP, Brasil.
  • Paulo Caleb Júnior de Lima SANTOS Laboratório de Genética e Cardiologia Molecular do Instituto do Coração da Faculdade de Medicina da Universidade de São Paulo, SP, Brasil.

DOI:

https://doi.org/10.14450/2318-9312.v25.e3.a2013.pp163-168

Keywords:

Diabetes mellitus, Drugs Adverse Reaction, Diagnostic Techniques and Procedures

Abstract

Diabetes mellitus (DM) is among the most significant chronic conditions of health. Current diagnostic criteria for DM suggest the following laboratory tests: fasting plasma glucose, glycated or glycosylated hemoglobin, oral glucose tolerance test, fructosamine, insulin, C-peptide, glucagon. This laboratory tests may present drug interferences, which are physiological or analytical. It was possible identify 30 drugs or group of drugs that have evidences of interfering in the major diagnostic tests of DM according reviewed literature. It is important to note that virtually in its entirety these drugs interfere in the blood glucose levels, and 81.5% of these contribute to increase these values. These drugs include OTCs (over-the-counter drugs), as paracetamol and acetylsalicylic acid, and steroidal anti-inflammatory, as dexamethasone and prednisolone, extensively used in the drug therapy. Likewise, drugs used for treatment of diabetic patients included in the RENAME as NPH insulin (neutral protamine Hagedorn), regular human insulin, glibenclamide, glicazide and metformin hydrochloride may interfere in the laboratory tests. Early diagnosis and appropriate treatment are needed in order to prevent major damage for patients presenting this under-diagnosed complex disease. In this context, drug interferences are significant findings in the laboratory tests that evaluate DM and should be acknowledged by involved healthcare professionals.

Downloads

Published

2013-09-30

How to Cite

KANASHIRO, D. H., GAMEIRO, F. D., COSTA JÚNIOR, V. L. da, SILVA, A. M., RIBEIRO NETO, L. M., MATSUI, R. S., … SANTOS, P. C. J. de L. (2013). Interferences in laboratory tests: diagnostic criteria for diabetes mellitus and major hypoglycemic agents. Infarma - Pharmaceutical Sciences, 25(3), 163–168. https://doi.org/10.14450/2318-9312.v25.e3.a2013.pp163-168

Issue

Vol. 25 No. 3 (2013)

Section

Review Article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).